Effects of 1-methyl-1,2,3,4-tetrahydroisoquinoline on the behavioral effects of cocaine in rats

Journal of Physiology and Pharmacology

Volumn 58, Issue 4, 2007, Pages 625-639

  Filip, M ^a   Antkiewicz Michaluk, L ^a   Zaniewska, M ^a   Frankowska, M ^a   Golda A ^a   Vetulani, J ^a   Przegalinski E ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

1 methyl 1,2,3,4 tetrahydroisoquinoline (1MeTIQ); Cocaine; Drug discrimination; Food; Locomotor activity; Self administration

Indexed keywords

1 METHYL 1,2,3,4 TETRAHYDROISOQUINOLINE; COCAINE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BRAIN DEPTH STIMULATION; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG ANTAGONISM; DRUG DISCRIMINATION; DRUG SYNTHESIS; FEEDING BEHAVIOR; LOCOMOTION; MALE; NONHUMAN; RAT;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; COCAINE; COCAINE-RELATED DISORDERS; CONDITIONING, OPERANT; CUES; DISCRIMINATION LEARNING; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEEDING BEHAVIOR; MALE; MOTOR ACTIVITY; RATS; RATS, WISTAR; REINFORCEMENT SCHEDULE; REWARD; SELF ADMINISTRATION; TETRAHYDROISOQUINOLINES;

EID: 38149034456     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Heidbreder CA, Hagan JJ. Novel pharmacotherapeutic approaches for the treatment of drug addiction and craving. Curr Opin Pharmacol 2005; 5: 107-118.
2. Di Chiara G. The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend 1995; 38: 95-137.
3. Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psych 2002; 159: 1642-1652.
4. Grimm JW, Lu L, Hayashi T, Hope BT, Su TP, Shaham Y. Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. J Neurosci 2003; 23: 742-747.
5. Preti A. BP-897 Bioprojet. Cur Opin Investig Drugs 2000; 1: 110-115.
6. Antkiewicz-Michaluk L, Filip M, Michaluk J, Romańska I, Przegaliński E, Vetulani J. An endogenous neuroprotectant substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ), prevents the behavioral and neurochemical effects of cocaine reinstatement in drug-dependent rats. J Neural Transm 2007; 114: 307-317.
7. Antkiewicz-Michaluk L, Michaluk J, Romańska I., Papla I, Vetulani J. Antidopaminergic effects of 1,2,3,4-tetrahydroisoquinoline and salsolinol. J Neural Transm 2000; 107: 1009-1019.
8. Vetulani J, Antkiewicz-Michaluk L, Nalepa I, Sansone M. A possible physiological role for cerebral tetrahydroisoquinolines. Neurotox Res 2003; 5: 147-155.
9. Antkiewicz-Michaluk L, Karolewicz B, Romańska I, Michaluk J, Bojarski A, Vetulani J. 1-Methyl-1,2,3,4-tetrahydroisoquinoline protects against rotenone-induced mortality and biochemical changes in rat brain. Eur J Pharmacol 2003; 466: 263-269.
10. Antkiewicz-Michaluk L, Wardas J, Michaluk J, Romańska I, Bojarski A, Vetulani J. Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone. Int J Neuropsychopharmacol 2004; 7: 155-163.
11. Patsenka A, Gołembiowska K, Ziemińska E, et al. Neuroprotective effects of 1-methyl-1,2,3,4-tetrahydroisoquinoline: in vitro and in vivo studies in rats. Pol J Pharmacol 2004; 56: Suppl 179.
12. Antkiewicz-Michaluk L, Michaluk J, Mokrosz M, et al. Different action on dopamine catabolic pathways of two endogenous 1,2,3,4- tetrahydroisoquinolines with similar antidopaminergic properties. J Neurochem 2001; 78: 100-108.
13. Antkiewicz-Michaluk L, Łazarewicz JW, Patsenka A, et al. The mechanism of 1,2,3,4-tetrahydroisoquinolines neuroprotection: the importance of free radicals scavenging properties and inhibition of glutamate-induced excitotoxicity. J Neurochem 2006; 97: 846-856.
14. Filip M, Gołda A, Zaniewska M, et al. Involvement of cannabinoid CB1 receptors in drug addiction: effects of rimonabant on behavioral responses induced by cocaine. Pharmacol Rep 2006; 58: 806-819.
15. Filip M, Frankowska M. Effects of GABAB receptor agents on cocaine priming, discrete contextual cue and food induced relapses. Eur J Pharmacol 2007; 571: 166-173.
16. Filip M, Bubar MJ, Cunningham KA. Contribution of serotonin (5-HT) 5-HT2 receptor subtypes to the discriminative stimulus effects of cocaine in rats. Psychopharmacology 2006; 183: 482-489.
17. Filip M, Frankowska M, Zaniewska M, et al. Involvement of adenosine A2A and dopamine receptors in the locomotor and sensitizing effects of cocaine. Brain Res 2006b; 1077: 67-80.
18. Kohno M, Ohta S, Hirobe M. Tetrahydroisoquinoline and 1-methyl-tetrahydro-isoquinoline as novel endogenous amines in rat brain. Biochem Biophysiol Res Commun 1986; 140: 448-454.
19. Przegaliński E, Gołda A, Frankowska M, Zaniewska M, Filip M. Effects of serotonin 5-HT1B receptor ligands on the cocaine- and food-maintained self-administration in rats. Eur J Pharmacol 2007; 559: 165-172.
20. 2, receptors. Psychopharmacology 1996; 123: 303-306.
21. Brebner K, Froestl W, Andrews M, Phelan R, Roberts DC. The GABA(B) agonist CGP 44532 decreases cocaine self-administration in rats: demonstration using a progressive ratio and a discrete trials procedure. Neuropharmacology 1999; 38: 1797-1804.
22. Filip M, Frankowska M, Zaniewska M, Gołda A, Przegaliński E, Vetulani J. Diverse effects of GABA-mimetic drugs on cocaine-evoked self-administration and discriminative stimulus effects in rats. Psychopharmacology 2007; 192: 17-26.
23. Roberts DC, Andrews MM. Baclofen suppression of cocaine self-administration: demonstration using a discrete trials procedure. Psychopharmacology 1997; 131: 271-277.
24. Childress AR, Hole AV, Ehrman RN, Robbins SJ, McLellan AT, O'Brien CP. Cue reactivity and cue reactivity interventions in drug dependence. NIDA Res Monogr 1993; 137: 73-95.
25. Jaffe JH, Cascella NG, Kumor KM, Sherer MA. Cocaine-induced cocaine craving. Psychopharmacology 1989; 97: 59-64.
26. Cornish JL, Duffy P, Kalivas PW. A role for nucleus accumbens glutamate transmission in the relapse to cocaine-seeking behavior. Neuroscience 1999; 93: 1359-1367.
27. Pulvirenti L, Maldonado-Lopez R, Koob GF. NMDA receptors in the nucleus accumbens modulate intravenous cocaine but not heroin self-administration in the rat. Brain Res 1992; 594: 327-330.
28. Wise RA. Neurobiology of addiction. Curr Opin Neurobiol 1996; 6: 243-251.
29. Ito R, Dalley JW, Robbins TW, Everitt BJ. Dopamine release in the dorsal striatum during cocaine-seeking behavior under the control of a drug-associated cue. J Neurosci 2002; 22: 6247-6253.
30. Kalivas PW, McFarland K. Brain circuitry and the reinstatement of cocaine-seeking behavior. Psychopharmacology 2003; 168: 44-56.
31. Neisewander JL, O'Dell LE, Tran-Nguyen LT, Castaneda E, Fuchs RA. Dopamine overflow in the nucleus accumbens during extinction and reinstatement of cocaine self-administration behavior. Neuropsychopharmacology 1996; 15: 506-514.
32. Garzon J, Fuentes J, Del Rio J. Effect of selective monoamine oxidase inhibitor drugs on morphine tolerance and physical dependence in mice. Neuropharmacology 1979; 18: 531-536.
33. Grasing K, He S. Effects of high-dose of selegiline on morphine reinforcement and precipitated withdrawal in dependent rats. Behav Pharmacol 2005; 16: 1-13.
34. Schiffer WK, Azmoodeh M, Gerasimov M, Volkow ND, Fowler JS, Dewey SL. Selegiline potentiates cocaine-induced increases in rodent nucleus accumbens opamine. Synapse 2003; 48: 35-38.
35. Houtsmuller EJ, Notes LD, Newton T, et al. Transdermal selegiline and intravenous cocaine: safety and interactions. Psychopharmacology 2004; 172: 31-40.
36. Wa̧sik A, Romańska I, Antkiewicz-Michaluk L. The effect of an endogenous compound 1-methyl-1,2,3,4,-tetrahydroisoquinoline on morphine-induced analgesia, dependence and neurochemical changes in dopamine metabolism in rat brain structures. J Physiol Pharmacol 2007; 58: 235-252.